Patents Examined by Matthew P Coughlin
  • Patent number: 12129246
    Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.
    Type: Grant
    Filed: February 28, 2024
    Date of Patent: October 29, 2024
    Assignee: Novartis AG
    Inventors: Daniela Angst, Philippe Bolduc, Matthew William Carson, Atwood Kim Cheung, Véronique Darsigny, Xiang Gao, Viktor Hornak, Keith Jendza, Rajesh Karki, Ajay Kumar Lal, Gang Liu, Justin Yik Ching Mao, Jeffrey M. McKenna, Erik Meredith, Muneto Mogi, Vivek Rauniyar, Liansheng Su, Ritesh Tichkule, Shuangxi Wang, Chun Zhang, Liang Zhao, Rui Zheng
  • Patent number: 12122759
    Abstract: The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: October 22, 2024
    Assignees: ELANCO ANIMAL HEALTH GMBH, THE KITASATO INSTITUTE
    Inventors: Dirk Heimbach, Satoshi Omura, Toshiaki Sunazuka, Tomoyasu Hirose, Yoshihiko Noguchi, Johannes Köbberling, Zhijie Wu, Shuibiao Fu, Wei Wu, Jinfeng Qiu, Liu He, Xudong Wei
  • Patent number: 12122776
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Patent number: 12122758
    Abstract: The invention provides a material comprising (i) a crown ether of formula (I) and/or (ii) a crown ether of formula (II), or a salt thereof, wherein each m independently is an integer from 1 to 8, each “” designates an optionally present bond and/or structure, each X independently is —N(R1)2, —N*(R1), —N**, —N*(R1)2+Z?, or —N**(R1)+Z?, provided at least one X is —N*(R1), —N**, —N*(R1)2+Z?, or —N**(R1)+Z?, wherein each R1 independently is hydrogen or C1-6 alkyl, each Z is optionally present and independently is a counterion to balance the charge on nitrogen, and * represents a bond to a remainder of the material, a method of making the material, and a method of using the material.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: October 22, 2024
    Assignee: Pall Corporation
    Inventors: Andrew Kocen, Rehanah Sejoubsari, Ahmad Arabi Shams Abadi
  • Patent number: 12116349
    Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: October 15, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Juergen Wichmann
  • Patent number: 12110292
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: October 8, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • Patent number: 12110280
    Abstract: A method for synthesizing cyclic carbonate monomers using carbon dioxide (CO2) is provided. The method also includes combining reagents to synthesize the cyclic carbonate monomer, the reagents including a substrate that is a 1,X-diol, where X is between 2 and 5, a base that is a tertiary amine, a promoter that is a multidentate, bis-tertiary amine base where nitrogens are separated by 2 to 4 carbon atoms, a solvent, and CO2.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: October 8, 2024
    Assignee: International Business Machines Corporation
    Inventors: Nathaniel H. Park, Victoria A Piunova, Dmitry Zubarev, Tim Erdmann, Pedro Arrechea, James L. Hedrick
  • Patent number: 12102608
    Abstract: A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): oleoylethanolamide (OEA) C18:1 60-65%? palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 ?1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8%? myristoylethanolamide (MEA) C14:0 0.02-0.15%?? mixture of glycerides ?4-6% glycerol ?6-8%. A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: October 1, 2024
    Assignee: EPITECH GROUP S.P.A.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Chiara Gomiero
  • Patent number: 12102712
    Abstract: A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone, fluocinonide, or clobetasol. The antifungal and steroid may be within a cream. In one example, a commercially available econazole nitrate cream may be used in conjunction with a commercially available fluocinonide cream or commercially available clobetasol cream to treat the affected skin area.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: October 1, 2024
    Assignee: CMPD Licensing LLC
    Inventor: Jay Richard Ray
  • Patent number: 12103904
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: October 1, 2024
    Assignees: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Patent number: 12103914
    Abstract: The present application discloses, in part, isolated, stable and biologically active menaquinol derivatives and their methods of use for the treatment of various diseases.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: October 1, 2024
    Assignee: Epizon Pharma, Inc.
    Inventors: John M. Rudey, Eric Stephen Gruff, Sam L. Nguyen
  • Patent number: 12098129
    Abstract: To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II): wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12, or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 24, 2024
    Assignees: LTT BIO-PHARMA CO., LTD., MUSASHINO UNIVERSITY
    Inventors: Tohru Mizushima, Ken-ichiro Tanaka
  • Patent number: 12098115
    Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: September 24, 2024
    Assignee: University of Florida Research Foundation, INC.
    Inventor: Alexander James Grenning
  • Patent number: 12098141
    Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
  • Patent number: 12098116
    Abstract: Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: September 24, 2024
    Assignee: UNITED THERAPEUTICS CORPORATION
    Inventor: Kenneth Phares
  • Patent number: 12091431
    Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: September 17, 2024
    Assignee: Aeromics, Inc.
    Inventors: Paul Robert Mcguirk, Robert Zamboni, Melanie Bevill, Stephan Parent
  • Patent number: 12091410
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Yoshito Terao, Masanori Kawasaki
  • Patent number: 12091411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: September 17, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Chris De Savi, Matthew M. Weiss, Xiao Zhu, Xiaozhang Zheng, Bruce C. Follows
  • Patent number: 12091398
    Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 17, 2024
    Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
    Inventors: Pan Li, Beidi Xu, Qiaodong Wen, Enguang Feng, Ji Wang, Yang Lu, Yu Zhou, Zhiyong Yu, Zhiying Huang
  • Patent number: 12084579
    Abstract: Disclosed herein are receptor-substrate complexes comprising an octacationic tricyclic cyclophane and a pyrrole dye complexed therein and methods of using and making the same.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: September 10, 2024
    Assignee: Northwestern University
    Inventors: James Fraser Stoddart, Wenqi Liu